Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

Perspective Therapeutics7 enrolled

Overview

The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.

This is a first-in-human study evaluating the suitability of \[203Pb\]VMT01 for SPECT/CT imaging and \[68Ga\]VMT02 for PET/CT imaging of MC1R-expressing metastatic melanoma. Study results will provide foundational data to develop imaging and dosing for future therapeutic trials of \[212Pb\]VMT01 for the treatment of metastatic melanoma. The study will be a cross-over study with the participants serving as their own comparator. Participants with positive FDG-PET scans for stage IV (or inoperable stage III) metastatic melanoma will undergo SPECT/CT scans utilizing \[203Pb\]VMT01 followed a few weeks later by PET/CT scans utilizing \[68Ga\]VMT02, or vice versa. The order of the imaging agents will be randomly assigned.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

SINGLE

Enrollment

Conditions

Melanoma (Skin)Melanoma Stage IV Melanoma, Uveal Melanoma, Mucosal

Interventions

[203Pb]VMT01DRUG

Diagnostic imaging radiopharmaceutical; by intravenous infusion

[68Ga]VMT02DRUG

Diagnostic imaging radiopharmaceutical; by intravenous infusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosed with Stage IV metastatic melanoma, or inoperable Stage III equivalent 2. Baseline fluorodeoxyglucose (FDG)-PET scan available from within 30 days prior to date of enrollment 3. Blood counts and metabolic results within protocol limits within 14 days prior to enrollment 4. Ability to lie flat and still for a minimum of two hours for imaging 5. Male and female participants with reproductive potential must agree to use highly effective contraception in preparation of the study, during the study, and for 4 weeks following the last dose of an investigative imaging agent 6. Documented life expectancy of at least 3 months Exclusion Criteria: 1. Active secondary malignancy 2. Prior treatment (for any reason) with radioactive nuclides; imaging tracers are acceptable 3. Pregnancy or breast feeding a child 4. Uncontrolled infection 5. Treatment with another investigational drug within 30 days prior to enrollment date 6. Any treatment with BRAF inhibitors since the baseline FDG-PET scan or plans for such treatment during the study 7. Kidney function not within protocol limits 8. BMI\>40 kg/m2 9. History of a condition resulting in anaphylaxis or angioedema

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of Participants with Study Imaging Agent-Associated Adverse Events (AE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Adverse Events (AEs) will be assessed for severity according to CTCAE v5.0 and for relatedness to each of the investigative imaging agents (\[203Pb\]VMT01 and \[68Ga\]VMT02). Assessments attributed as possibly, probably, or definitely related to the imaging agent will be considered related.

Time frame: Visit 1 (Day 1) through Visit 5 (approximately Day 60 but could extend up to Day 108); ongoing Serious Adverse Events (SAE) will be followed for no longer than Day 65 or 30 days from the date of the SAE report (whichever is later).

Biodistribution of [68Ga]VMT02

Biodistribution will be calculated by utilizing PET/CT scans.

Time frame: 12 hours

Biodistribution of [203Pb]VMT01

Biodistribution will be calculated by utilizing SPECT/CT scans.

Time frame: 24 hours

Peak Plasma Concentration (Cmax) of [203Pb]VMT01

Cmax will be determined by blood sampling and direct radioactivity measurements.

Time frame: 24 hours

Area Under the Plasma Concentration Versus Time Curve (AUC) for [203Pb]VMT01

AUC will be determined by blood sampling and direct radioactivity measurements.

Time frame: 24 hours

Renal Excretion of [203Pb]VMT01

Renal excretion will be determined by urine sampling and direct radioactivity measurements.

Time frame: 24 hours

Modeling of [203Pb]VMT01 Dosimetry

Dosimetry will be modeled by utilizing the SPECT/CT scans.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

MC1R Expression Correlation Between Archived Tumor Tissue and Study Imaging

Archived (previously collected) tumor tissue will be tested for MC1R expression and compared to study images obtained using MC1R targeted imaging agents, \[203Pb\]VMT01 and \[68Ga\]VMT02. The data will be assessed for an association between positive tissue and positive images.

Time frame: Historical tissue sample (collected <365 days before study enrollment) compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging

Cancer Site Correlation Between Standard of Care Imaging Compared to Study Imaging

Sites of cancer detected previously by imaging will be compared to the presence or absence of positive imaging scans with the study agents, \[203Pb\]VMT01 and \[68Ga\]VMT02.

Time frame: Historical imaging information compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging

Dosimetry will be Calculated for each Study Imaging Agent by Measuring the Cumulative Absorbed Dose of Radiation to the Participant's Individual Organs and Tumors

For a given participant, dosimetry calculations will be compared between the two imaging agents with respect to cumulative absorbed dose of radiation.

Time frame: Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging